Observational Study, Use of Canakinumab Administered Subcutaneously in the Treatment COVID-19 Pneumonia

Observational Study on the Use of Canakinumab Administered Subcutaneously in the Treatment of Patients With COVID-19 Pneumonia

The study is configured as a retrospective and prospective observational study. The study will be multi-center and will involve all COVID-19 pneumonia patients treated with canakinumab administered subcutaneously.

Inclusion Criteria:

• patients with COVID 19 who have received or are candidates to receive treatment with canakinumab subcutaneously
• Age> 18 years
• Pneumonia diagnosed with Chest X-ray / or Chest CT

Exclusion Criteria:

• Patients with Covid19-related pathology in the context of another cause of major admission (trauma, surgery)